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ABSTRACT 
Background: Most critically ill patients experience pain, fear, and anxiety as part of their illness 
while in the Intensive Care Unit (ICU). These emotions may be amplified during the provision of 
life-sustaining therapies, such as mechanical ventilation (MV).  Pharmacotherapy including 
analgesics, sedatives, and antipsychotics are considered the standard of care to optimize patient 
safety and comfort during MV. Although the use of analgesics, sedatives, and antipsychotic 
therapies in the ICU is commonplace; adverse effects, unpredictable pharmacokinetics, and 
inappropriate dose titrations often hinder achieving the optimal level of effectiveness.2-4  Under-
treatment may lead to significant pain, agitation, myocardial ischemia, ventilator dyssynchrony, 
intravenous line removal, self-extubation, and post-discharge complications, including post-
traumatic stress disorder (PTSD).  In contrast, over-sedation has been associated with prolonged 
mechanical ventilation, development of decubitus skin ulcers, hospital-acquired infections, 
PTSD, delirium, prolonged ICU and hospital length of stay (LOS), and an increase in overall 
hospital costs. The aims of this study were to see if the use of analgosedation (fentanyl alone) 
would be non-inferior to conventional regimen (CR) in time-to-extubation and determine factors 
that affect ICU length of stay, mortality and re-intubation within 24 hours.     
Methods: The study design was a retrospective matched observational study. After 
inclusion/exclusion criteria were applied 254 patients were identified in the study group. 
Propensity score matching was used to ensure that treatment groups were similar in terms of 
admission diagnosis, intubation reason, and APACHE II score. A total sample of 86 patients 
were selected into the analytical group with 43 patients each in the fentanyl alone group (FA) 
and CR group to show that the effect of fentanyl alone in a sedation protocol is not worse than 
that of the conventional regimen   Kaplan Meier methods and Cox proportional hazard models 
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were used to analyze the primary outcome of interest; time-to-extubation. Covariates included in 
the Cox regression model included age, gender, ICU days, substance abuse history, number of 
admissions in the previous year, and insurance status. Using general linear regression modeling, 
we explored the effect of patient socio-demographic and clinical characteristics on ICU length of 
stay. Binary logistic regression modeling was used to assess the effect of patient socio-
demographic and clinical characteristics risk of ICU mortality, and also for re-intubation within 
24 hours.  
Results:  Differences in patient socio-demographics characteristics between the two groups was 
observed for ventilator days (5.7 days FA vs. 8.3 CR p = 0.04) and history of psychiatric 
problems and medication (17.4% vs. 2% p < 0.001). In the Cox proportional hazards regression 
models, the univariate/unadjusted models demonstrated non-inferiority between the two groups 
[HR= 0.7, 95% CI = (0.47, 1.18). This was confirm after adjusting for patient socio-demographic 
and clinical characteristics HR= 0.99, 95% CI = (0.6, 1.63). The ICU length of stay was 
significantly different between the two treatment groups in both the univariate model [HR= 0.9, 
95% CI = (0.83, 0.93)] and after adjusting for patient socio-demographic and clinical 
characteristics [HR= 0.9, 95% CI = (0.82, 0.92)]. Females were observed to likely have reduced 
time-to-extubation in the adjusted model [HR = 0.5, 95% CI = (0.32, 0.88)]. In the analyses on 
secondary outcomes, ICU length of stay was determined to depend on the gender of the patient. 
Females were more likely than males to be admitted for a shorter length of time in the ICU (p < 
0.001). There was no statistically significant difference in the duration of admission in the ICU 
between patients who received FA and CR (p =0.3). In the assessments of the risks of death in 
the ICU and re-intubation within 24 hours whiles on admission at the ICU, the binary logistic 
v 
 
regression models comparing the risks in the FA and CR groups showed that the treatment 
groups were similar in terms of the risks.  
Discussion: It was shown that Fentanyl-Alone in a sedation protocol was not worse off than that 
of the Conventional regimen in terms of duration of intubation.  A larger trial is needed to 
determine if the analgosedation with fentanyl will provide any superior benefits in the duration 
of intubation. In this trial females demonstrated a much reduced length of time intubated 
compared to males and also the duration of admission at the ICU.  A much structured study with 
sufficient power to determine the nature and intensity of these differences will needed.  If the 
findings here are confirmed, it should provide some meaningful directions in health care 
particularly the relationship between gender and these outcomes. Finally this trial adds to the 
literature by being the first to use time-to-event analysis in patients receiving analgosedation. 
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INTRODUCTION 
The Public Health Issue 
Most critically ill patients experience pain, fear, and anxiety as part of their illness while 
in the Intensive Care Unit (ICU). These emotions may be amplified during the provision of life-
sustaining therapies, such as mechanical ventilation (MV). Thirty-seven percent of all patients 
who are admitted into an ICU will be placed on a mechanical ventilator.1 Pharmacotherapy 
including analgesics, sedatives, and antipsychotics are considered the standard of care to 
optimize patient safety and comfort during MV.2  As with all other therapeutics, a complete past 
medical history with regard to psychological function and current medication use (e.g. opioids 
and benzodiazepines) must be obtained in order to understand the baseline needs of the 
individual patient.  It is important to note that each underlying disease state will directly 
influence the choice of pharmacotherapy; therefore, applying evidence-based medicine to the 
ICU population should be focused towards prioritizing patient comfort and outcomes, given the 
principle condition and comorbidities.  
Although the use of analgesics, sedatives, and antipsychotic therapies in the ICU is 
commonplace; adverse effects, unpredictable pharmacokinetics, and inappropriate dose titrations 
often hinder achieving the optimal level of effectiveness.2-4  Under-treatment may lead to 
significant pain, agitation, myocardial ischemia, ventilator dyssynchrony, intravenous line 
removal, self-extubation, and post-discharge complications, including post-traumatic stress 
disorder (PTSD).  In contrast, over-sedation has been associated with prolonged mechanical 
ventilation, development of decubitus skin ulcers, hospital-acquired infections, PTSD, delirium, 
prolonged ICU and hospital length of stay (LOS), and an increase in overall hospital costs.5,6  
However, use of a multidisciplinary care team and an ICU-specific sedation and analgesia 
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protocol can limit morbidity and mortality defined above.2,7,8  Delirium is a strong predictor of 
adverse outcomes and is one of the first iatrogenic events following admission to the ICU that 
has demonstrated long-term and short-term effects9. These affects include increased mortality 
and morbidity10. Patients who experience delirium have increased ICU and hospital LOS, which 
are associated with an increase in cost to the health system.11 
The majority of patients in the ICU, who experience pain, will experience pain recall 
after transferring out of the ICU.12-14 Therefore, according to the 2013 Clinical Practice 
Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the 
Intensive Care Unit, pain should be monitored and treated.4  These guidelines are meant to: (a) 
ensure that patients are pain free and comfortable, and (b) reduce ventilator time. The ideal 
regimen for patients receiving MV should have adequate coverage for pain and anxiety, as well 
as providing favorable pharmacokinetics (rapid onset/offset of action, short half-life, few drug 
interactions, and minimal accumulation).15 Fentanyl and other opioids have been reviewed as 
monotherapy, meaning when taken in conjunction with other agents they successfully control 
pain and provide sedative for those mechanically ventilated due to a short onset of action. The 
Society of Critical Care Medicine (SCCM) guidelines state that Fentanyl may provide immediate 
sedation and comfort.  This approach is referred to as “analgosedation”; however, there is very 
little data to support this strategy.16   
Purpose of this Study 
This study, through a retrospective cohort of medical ICU patients, compared a Fentanyl-
alone (FA) regimen to a conventional regimen (CR) to show that the effect of fentanyl alone in a 
sedation protocol is not worse than that of the conventional regimen in terms of critical outcomes 
like the duration of admission in the ICU, duration of intubation of patients, risk of mortality 
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whiles on admission at the ICU, and risk of re-intubation with 24 hours after a temporary 
extubation.  The conventional regimen is defined as receiving a sedation medication (Propofol, 
Midazolam, Lorazepam, or Dexmedetomidine) continuously in tandem with an analgesic 
medication (Fentanyl).   Since there is minimal evidence on Fentanyl as monotherapy, the study 
findings could potentially change practice, resulting in improved patient care and reduced 
exposure to potential complications associated with mechanical ventilation.   The results of this 
study will help clinicians determine optimal medications for patients in an ICU who are 
mechanically-ventilated to help decrease ventilator-dependent and hospital days.  
Aims 
In a retrospective cohort of medical ICU patients, this study we compared a Fentanyl-
alone (FA) group to a conventional regimen.  Conventional regimen is defined as receiving a 
sedation medication (Propofol, Midazolam, Lorazepam, or Dexmedetomidine) continuously in 
tandem with an analgesic medication (Fentanyl). 
1. The decrease in sedation will not be associated in any reduced benefits  in ventilator 
support compared to the conventional regimen 
2. To determine the effects of analgosedation (Fentanyl) on ICU length of stay, ICU- 
and ICU-mortality, and the proportion of re-intubations within 24 hours among the 
cases examined 
Inclusion/Exclusion Criteria  
Selection into the study required the patient to have been admitted to the MICU at the Via 
Christi Hospital on St. Francis St from 1/1/2010 to 5/31/2013.   Patients were also required to 
have been mechanically ventilated for a minimum of forty-eight hours and had received 
analgesic medications (Fentanyl) and/or sedation medication (propofol, midazolam, lorazepam, 
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and Dexmedetomidine. Patients were excluded if they were prisoners, pregnant, minors, 
receiving neuromuscular blockers (NMBA), were admitted for trauma or have a central nervous 
system pathology (acute stroke, traumatic brain injury, intracranial hemorrhage, active seizures, 
end stage Parkinson's, dementia, post cardiac arrest etc.) Finally, patients were excluded if they 
were receiving spinal or epidural infusions.  
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BACKGROUND AND LITERATURE REVIEW 
Pain Management among Critically Ill Patients 
Analgesics 
Pain occurs in critically-ill MV patients for various reasons, including discomfort from 
surgical wounds and provision of endotracheal tubes.  From the patient’s perspective, MV can be 
uncomfortable.  Mechanical ventilation prevents patients from communicating effectively, 
therefore symptoms of pain, delirium, and hypoxemia can manifest as “agitation”.  This agitation 
can lead to self-extubation and potential harm to the patient and staff.17  According to some 
evidence, adequate pain control is vital and potentially achieved with little to no sedative 
administration.16  It is also important to remember that a significant number of critically ill 
patients expire during their ICU stay and providing comfortable transition to death is key for the 
family and presumably the patient.  
Sedation  
Sedation is the provision of analgesia and satisfaction of the anxiolytic, hypnotic, and 
amnestic needs of the patient.  Sedatives are frequently used to facilitate care in the ICU to 
prevent recall of treatment and reduce anxiety.  This care includes primary nursing 
responsibilities such as endotracheal suctioning, wound dressings, and prevention of adverse 
events such as self-extubation.18  Patients may experience anxiety from the events surrounding 
an ICU admission secondary to an inability to communicate and/or sleep deprivation.2,16-20  
Another use for sedation includes the desire to produce an amnestic effect in order to blunt the 
overall ICU experience, pain recall and lessen the risk of post-traumatic stress disorder 
(PTSD).19  However, this practice has been challenged by recent literature stating that less 
sedation may reduce the risk of PTSD.20 
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However, pain assessment in patients who are mechanically-ventilated is difficult due to 
the patient’s inability to communicate.  Pain assessment becomes subjective due to altered 
sensorium and decreased mentation.  It is recommended that clinicians should assess non-
communicative patients with subjective measurements of body movement, ventilator synchrony, 
and facial expressions, in addition to dynamic changes in vital signs (heart rate, respiratory rate, 
and blood pressure).2,21-24 
Sedation Medications   
The most common sedation medications in current use include Propofol, Lorazepam, 
Midazolam and Dexmedetomidine.  Propofol is commonly used because it has a short half-life 
and has predictable sedative and hypnotic effects. This allows Propofol to be administered to 
patients who require frequent neurological exams.  Thus, titration to clinical response and daily 
evaluation of sedation are important during use of Propofol infusions for ICU sedation.  It is 
chiefly eliminated by hepatic conjugation to inactive metabolites, which are excreted by the 
kidney. Neither metabolism nor clearance has been affected by hepatic and renal insufficiency, 
which makes it a desirable pharmacotherapeutic agent in the ICU. However, Propofol also has 
potential adverse effects including Propofol Infusion Syndrome (PRIS), infection, and 
hypertriglyceridemia, if high-doses are administered for greater than 72 hours.25,26   
Benzodiazepines are extensively used sedatives in the ICU and exert their effect by 
binding to the gamma-aminobutyric acid receptor (GABA) complex.27-30  Benzodiazepines 
induce anterograde amnesia, respiratory depression, and are opioid-sparing.  Two 
benzodiazepines that have been studied in MV ICU patients include Lorazepam and Midazolam.  
Both of these drugs have been shown to be effective in reducing anxiety and improving comfort 
to the MV patient.31  Midazolam and Lorazepam are highly lipophilic and accumulate in 
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peripheral tissues during continuous intravenous infusion, which has been shown to increase the 
half-life of the medication and the pharmacodynamic effects.6  The effects of accumulation may 
be reduced by providing a daily drug holiday and maintaining the lowest infusion dose that 
produces satisfactory sedation. 32-35 Benzodiazepines have been shown to increase the risk of 
delirium in approximately 70% of mechanically ventilated patients.36 Among medical ICU 
patients, delirium has been shown to be a strong predictor of increased ventilator duration, longer 
ICU stay, long-term cognitive impairment, or even death.37  
Dexmedetomidine (Precedex©) is a centrally acting alpha-2 agonist.  Dexmedetomidine 
promotes anxiolysis and sedation; however, it does not cause respiratory depression.38  The side 
effect profile consists of hypotension and bradycardia, which can lead to complete heart block.  
Dexmedetomidine has shown the ability to reduce the amount of time a patient is delirious and 
has been proven to be safe for extended infusions. 39 
Pain Medications  
Fentanyl is a highly lipophilic synthetic opioid with a rapid-onset of action (1-3 minutes) 
and a short duration of activity upon intravenous administration.  This makes Fentanyl ideal for 
clinical situations that require rapid and short-sustained analgesic activity.  Fentanyl has little 
effect on the cardiovascular system and can be used without issue in hemodynamically unstable 
patients. Opioids, such as Fentanyl, have been reviewed as monotherapy, or in conjunction with 
other agents, to help control pain for those mechanically ventilated due to its short onset of 
action.  The SCCM guidelines state that Fentanyl may provide immediate sedation and comfort; 
however, there is very little data to support this.4  One published multi-centered study compared 
Remifentanil with a “conventional regimen”.16  Patients were randomized to receive either 
Remifentanil with or without Propofol vs. conventional regimen, which was defined as sedation 
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agent (Propofol, Midazolam, or Lorazepam) or analgesic (Morphine or Fentanyl).  Infusions 
started simultaneously Table 1.  Remifentanil was administered alone until a ceiling dose was 
reached; then propfol was added.  The primary outcome variable was duration of MV, defined as 
the time from the start of the study regimen until extubation.  Patients who received conventional 
sedation were on the ventilator 1.2 days longer compared to patients who received a 
Remifentanil-based analgesia Table 2.16  
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Table 1. Exposure of Medication Combination in the Rozendaal, FW et al.16 
Drug, % 
Conventional Sedation & Analgesia, 
%* 
n = 109 
Remifentanil 
n = 96 
Analgesic Meds   
Morphine 58% - 
Fentanyl 38% - 
Remifentanil - 100% 
Sedation Meds   
Midazolam 81% - 
Propofol 46% 65% 
Lorazepam 7% - 
* Does not add up to 100%, some patients received more than one therapy 
 
  
   
Table 2. Outcomes of Analgosedation in the Rozendaal, FW et al Study16   
 
Ventilator Outcomes 
Conventional 
Sedation & 
Analgesia 
n = 109 
Remifentanil 
 
n = 96 
 
P Value 
Duration of MV(mean days) + (95% CI) 5.1 (3.5, 6.7) 3.9 (2.6, 5.2) 0.025 
Weaning time (mean hours) + (95% CI) 24.8 (21.4, 28.1) 5.9 (0.8, 11) 0.0001 
 
 
 
 
 
 
10 
 
HYPOTHESIS  
ICU patients from 1/1/2010 to 5/31/13, who were mechanically ventilated and obtained 
analgesia alone from Fentanyl alone in a sedation protocol is not worse of in terms of the length 
of time-to-extubation than those who received conventional sedation, defined as a continuous 
infusion of a sedation agent (Midazolam, Lorazepam, Propofol, or Dexmedetomidine) in tandem 
with analgesia (Fentanyl).  
STUDY DESIGN 
This research was a retrospective, observational, cohort study. The researcher conducted 
a retrospective chart review of mechanically ventilated patients admitted to the medical ICU at 
Via Christi Hospitals, Wichita, Inc. between January 1, 2010 and May 31, 2013. (Figure 1)   
Conceptual Model 
Figure 1. Structure of Analytical Strategy 
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Study Sample and Analytical Sample 
As shown in Figure 2 the identification of all patients in the Medical ICU who were on 
mechanical ventilation (MV) during the period of January 1, 2010 through May, 31 2013 
garnered 254 potential subjects for analysis after meeting inclusion and exclusion criteria (Table 
3).  However, in an effort to ensure that the treatment groups were balanced in terms of critical 
confounding factors, propensity scoring matching methods (described below) were applied 
which after isolating patients on the Fentanyl-Alone (FA) regimen, selected a patient matched to 
be similar in the matching characteristics (detailed below) who had received the Conventional 
Regimen (CR).  The resulting, propensity-balanced, observational cohorts contained 43 patients 
in each study group. 
Figure 2. Study Sample and Analytical Sample 
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STUDY LOCATIONS 
The site involved in this research includes Via Christi Hospitals, Wichita Inc., St. Francis 
Campus. 
As this project is a retrospective chart review, access was only allowed for VCH-W 
Principal Investigator to on-line hospital patient records (Mirror Image, respiratory records, and 
on-line hospital pharmacy records (Siemens Pharmacy System) was required.  
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METHODS 
This was a retrospective chart review approved by The University of Kansas School of 
Medicine-Wichita Human Subjects Committee and Via Christi Health Institutional Review 
Board.  The study was based on data routinely collected in hospital records for patients admitted 
to the Medical ICU (MICU).  All patients admitted to the MICU at Via Christi Hospitals, 
Wichita Inc., Saint Francis Campus, who were placed on a MV between January 1, 2010 and 
May 31, 2013 and who met inclusion criteria, were selected.  The exclusion criteria are specified 
in Table 3.  The process of selection had it that patients were first identified from a pharmacy-
based routine report based on medication prescribed, and use of ventilator.  Once a patient list 
was obtained, the researcher reviewed all relevant information and entered the extracted 
information into an electronic database (Microsoft Excel and Access) for analysis. All statistical 
analyses were carried out using SAS software 9.2 (SAS Institute Inc., Cary, NC). 
Table 3. Subject Inclusion/Exclusion  
Inclusion Criteria (eligible to participate) Exclusion Criteria (ineligible to participate) 
● Age 18 or older 
● Mechanically ventilated ≥48 hours 
● Admitted to Via Christi Hospital on St. 
Francis Street between 1/1/2010 and 
5/31/2013 
● Patients receiving IV infusions of 
Lorazepam, Midazolam, 
Dexmedetomidine, Propofol, and Fentanyl 
● Prisoners 
● Pregnant women 
● Patients who were receiving neuromuscular 
blockers outside rapid sequence intubation 
● Trauma patients 
● Burn patients 
● Patients with serious central nervous 
pathology (acute stroke, traumatic brain 
injury, intracranial hemorrhage, active 
seizures, end stage Parkinson's, dementia, 
post cardiac arrest etc.) 
● Epidural or spinal epidurals 
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BALANCING GROUPS: FENTANYL-ALONE & CONVENTIONAL 
REGIMEN 
 
Patients in the Fentanyl-Alone (FA) group were matched to a comparison group of 
Conventional Regimen (CR) using propensity scoring techniques as depicted in Figure 1.   The 
propensity score matching algorithm determined the propensity score defined as an individual's 
probability of being treated with the intervention of interest relative to the alternative treatment 
given an appropriate set of patient socio-demographic and clinical characteristics about that 
individual. The purpose of propensity score matching is to reduce the numbers of potential 
confounders between the two groups, thus balancing the observational groups on factors 
expected to affect the dependent measures.  These “matching factors” were selected based on 
their potential to reduce differences between the groups.  In this study, the matching factors were 
patient Apache scores and diagnosis at admission. 
APACHE Score 
The APACHE scoring system was designed to aid in determining ICU admission criteria.  
Today, the APACHE II scoring system is used as a predictive model for mortality.  Breakpoints 
of less than 25 and greater or equal to 25 are based on data demonstrating that patients with high 
APACHE scores have approximately 55% higher mortality rates compared to a 30% mortality 
rate for APACHE lower scores.   
Admitting Diagnosis 
The admission diagnosis was selected due to the expected variation in mortality and 
morbidity for each diagnosis.  Congestive heart failure (CHF), chronic obstructive pulmonary 
disease (COPD), cancer, infection, and other conditions were anticipated to provide similar 
mortality and morbidity characteristics in both FA and CR groups.  
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Ventilator Modes 
The ventilator mode can affect sedation and analgesic requirements. All of the patients in 
this study were on conventional ventilator modes, which should reduce the requirements needed 
for sedation and analgesia.  
Figure 3. Propensity Matching Criteria 
 
* CHF = Congested Heart Failure 
* COPD = Chronic Obstructive Pulmonary Disease 
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OUTCOMES 
Primary Outcome Measure 
The primary outcome measure was duration (days) from intubation to extubation within 
28 days from ICU admission. Patients who died whiles on admission at the ICU and during the 
period of intubation, had extubation not according to the medical protocol, was transferred  to 
another institution, or was still intubated at the end of the 28 days of observation were considered 
censored to the time-to-event analysis.  This 28-day cutoff in patient observation is according to 
a Food and a Drug Administration (FDA) recommendation for new pharmacotherapeutic agents 
designed for critically-ill patients, which suggests 28 days to be the optimal time to determine 
beneficial outcomes in the critically-ill. 40-42 The study time frame and structure of the primary 
outcome measure are shown in Figure 4. 
Figure 4. Primary Outcome Measure and Timeline 
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Secondary Outcome Measures 
Secondary outcome measures included:  ICU length of stay, ICU mortality, and 
proportion of re-intubations within 24 hours. ICU length of stay was measured from date of ICU 
admission to ICU discharge. Mortality was determined by discharge disposition of death in the 
electronic record and location when the event occurred. Re-intubation within 24 hours was used 
as a surrogate marker for failed extubation.  
Covariates 
Covariates that were used in this study included gender, dosage of medication, substance 
abuse history, Source of payment, BMI, count of patients re-intubated within 24 hours of 
extubation and number of admissions in past year.  
Statistical Analysis: Descriptive Analysis 
Summary description of baseline characteristics of patients in the two treatment groups 
were assessed using frequency distributions for categorical variables and means and standard 
deviations for continuous variables.  We compared all baseline variables for both groups to 
identify any clinically meaningful imbalances that may influence the primary outcome.  All 
analyses were conducted using SAS software 9.2 (SAS Institute Inc., Cary, NC) 
Multivariable Analytical Strategy: To address the primary and secondary outcomes that 
comprehensively addressed the research objectives of this study, we adopted the following 
multivariable analysis strategy (Shown in Table 4).   
First, the univariate unadjusted effect of patient characteristics on patient time-to-
extubation (days) compared between the propensity-balanced groups was conducted.  The 
influence of key predictors on patient probability of extubation was further examined in a 
multivariable Cox Proportional Hazards regression model.    
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Table 4. Definition of Variables 
Variable Definition 
Ventilator days Time (days) spent on the mechanical ventilator 
ICU days Time spent admitted to the ICU 
ICU mortality  Patients who died in the ICU 
Re-intubation within 24 hours Patients placed back on the ventilator < 24 hours from 
extubation 
 
Table 5. Analytical Strategy 
Outcomes Measure 
Time-to-extubation Kaplan Meier & Cox Proportional Hazard Model
ICU days Linear Regression 
ICU mortality Logistic Regression 
Re-intubation within 24 hours Logistic Regression 
 
Further analyses were conducted to understand the factors that predict the secondary 
outcomes: number of ICU days, mortality within the ICU and re-intubation within 24-hours of 
extubation.   
Statistical Analysis: Analysis of Primary Outcome Measure 
We compared the primary outcome (time-to-extubation) between FA patients and the CR 
group.  Kaplan-Meier (KM) survival analysis methods were utilized to determine the differences 
in time-to-extubation between the two treatment strategies.  Unadjusted rates of time-to-
extubation between the propensity-balanced cohorts, with 95% confidence intervals, were 
compared using log-rank tests.  In addition, Cox proportional hazards regression model was used 
to determine the effects of patient and disease characteristics on the likelihood of extubation and 
to further examine their influences on the measure of effect, while adjusting for possible 
confounding variables.  
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The Cox proportional hazards regression model was used to determine if admission age, 
gender, substance abuse history, ICU length of stay, BMI categorical, race, Insurance status, re-
intubation within 24 hours, and number of hospital visits in the last year to provide insight to the 
difference found between the two groups in time-to-extubation.  The predictors were selected 
based on the assumed clinical effect each predictor has on successful extubation. Forest plots 
were used to present the parameter estimates. 
Statistical Analysis:  Analysis of Secondary Outcome Measures 
ICU Length of Stay 
The t-test was used to compare the statistical difference in ICU length of stay. The linear 
regression model was then used to determine if age, psychiatric history, substance abuse history, 
study group, race source of payment, gender, re-intubation within 24 hours, BMI,  number of 
admissions in past year, and substance abuse history could provide insight to differences between 
the two propensity-balanced groups in ICU length of stay.  The predictors were selected based on 
an assumed clinical effect on ICU length of stay, and evidence in the literature.16,17  The critical 
coefficients included study group, BMI, age, substance abuse history, and psychiatric history. 
Different sedation medications have significantly different half-lives and therefore could 
account for increase in length of ICU stay. Patients who are in the obese BMI category are 
associated with increase length of stay.  Re-intubation within 24 hours is an assessment of 
extubation failure and is associated with an ICU length of ICU stay. There is a potential effect 
source of payment, gender, number of admissions in past year, and substance abuse history with 
ICU length of stay.  The specification of the model is shown below.  
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LOS 	β β age 	β 	Psychiatric	history	 	β Study	group 	β Race
	β 	Substance	abuse	history 	 	β Source	of	payment 	β
	number	of	admissions	in	past	year 	 	β 	 Gender	 	β 	 Re
intubation	within	24	hours 	 	β 	 BMI	Groups 
 
ICU Mortality 
ICU mortality was defined as a dichotomous variable (Yes/No). Due to the potential low 
cell counts, Fisher’s exact test was chosen to determine any association ICU mortality outcomes 
and treatment groups.  This binary logistic regression modeling technique was used to determine 
if patient characteristics such as age, gender, treatment group, race, psychiatric history, source of 
payment, number of admissions in past year, BMI group, and substance abuse history will 
explain ICU mortality differences between the two groups.  The predictors were selected based 
on their assumed effect each predictor has on mortality. Study grouping it was expected   would 
determine if sedation choices made a difference in ICU Mortality, which would in turn affect 
duration to extubation.  BMI categories, it was supposed, might have some effect on mortality 
through increased half-life of pharmacotherapy and increased morbidity of patients with amassed 
BMI.  Psychiatric history was selected on the assumption that patients who have mental illness 
may have an increased risk of mortality. Age and gender are used in the model to determine their 
impact on mortality. Source of payment, number of admissions in past year, and substance abuse 
history was also assessed as potential confounders of the risk of ICU mortality. 
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logit mortality:
Yes
No
	β β age 	β 	Psychiatric	history	 	β Study	group 	β
Race 	β 	Substance	abuse	history 	 	β Source	of	payment 	β
	number	of	admissions	in	past	year 	 	β 	 Gender	 	β 	 Re
intubation	within	24	hours 	 	β 	 BMI	Groups	 
 
Proportion of Re-intubations within 24 Hours 
Re-intubation within 24 hours was defined as a dichotomous variable (Y/N). Due to the 
potential low cell counts, Fisher’s exact test was chosen to determine any association re-
intubation within 24 hours outcomes and treatment groups.  This binary logistic regression 
modeling technique was used to determine if patient characteristics such as age, gender, 
treatment group, race, psychiatric history, source of payment, number of admissions in past year, 
BMI group, and substance abuse history will explain re-intubation within 24 hours differences 
between the two groups.  The predictors were selected based on the assumed effect each 
predictor has on re-intubation.  Study group   would determine if sedation choices made a 
difference in re-intubation, which would in turn effect duration to extubation.  BMI categories 
might have an effect on re-intubation due to the lipophilicity of the pharmacotherapeutic agents. 
Psychiatric history was selected on the assumption that patients who have mental illness may 
have an increased risk of re-intubation. Age and Gender is used in the model to determine their 
impact on re-intubation. There is a potential effect source of payment, number of admissions in 
past year, and substance abuse history with ICU re-intubation.    
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logit re intubation:
Yes
No
	β β age 	β 	Psychiatric	history	 	β Study	group 	β
Race 	β 	Substance	abuse	history 	 	β Source	of	payment 	β
	number	of	admissions	in	past	year 	 	β 	 Gender	 	β 	ICU	los
	 	β 	 BMI	Groups	 
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Results 
Patients were identified from the hospital electronic health records by sedation agents 
used during ICU stay.  A total of two hundred and fifty-four patients met the requirements for 
inclusion into the study.  Propensity scoring matched patients based on APACHE scores, 
admission diagnosis, and intubation reason.  Propensity scoring was used to reduce confounders 
between the two groups, and achieve the best balancing in these observational groups. 
A total of eighty-six patients were included in the study with forty-three in each group. 
The mean [+ Standard deviation (SD)] or percentages were reported between the two groups: age 
FA 62..5 + 13.9 vs. CR 65.2 +  14.3 (p =0.382), gender FA  65% were male vs. CR 48.% male (p 
= 0.127), ICU days  FA 10.6 + 11.6 vs. CR 13.5 + 10.5 (p=0.227) and ICU mortality FA 19.8% 
vs. CR 16.3% (p=0.5).  There was no difference between the groups in relationship to the BMI 
categories (p = 0.9). There was no difference between the groups average number of prior 
admissions in the last year. 0.7 + 1.2 FA and 1.1 + 1.3 (p = 0.095).  The only difference between 
the two groups was a reduction in ventilator days – the primary outcome measure   5.7+ 4.7 FA 
and 8.3+ 6.4 CR, (p = 0.039).  Insurance was classified into three groups with public 65% and 
private insurance 16%. The insurance classification of “other” was 8%, which included mostly 
patients without any insurance or customers, who were cash paying. Table 6 highlights the 
demographics of the study populations. 
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Table 6. Demographics and Descriptive Variables 
Study Group 
Fentanyl-
Alone 
(FA) 
N = 43 
Conventional 
Regimen 
(CR)  
N = 43 Total P value 
Age, (Mean + SD) 62.5 + 13.9 65.2 + 14.3 63.8 + 14.1 0.382 
Gender (Male), n (%) 28 (65.1) 21 (48.8) 49 (57) 0.127 
Admission Diagnosis*, n (%)       0.945 
Infection 
Chronic Obstructive Pulmonary 
Disease  
Other 
Renal failure 
Congested Heart Failure 
Diabetic ketoacidosis 
17 (19.8) 
12 (13.9) 
8 (9.3) 
3 (3.5) 
2 (2.3) 
1 (1.2) 
16 (18.6) 
14 (16.3) 
5 (5.8) 
4 (4.7) 
4 (4.7) 
0 (0) 
33 (38.4) 
26 (30.2) 
13 (15.1) 
7 (8.1) 
6 (7) 
1 (1.2) 
 
Reason for Intubation*, n (%)       0.965 
Pneumonia 
Chronic Obstructive Pulmonary 
Disease 
Overload 
Acute Respiratory Distress Syndrome
Overdose 
Other 
15 (17.4) 
8 (9.3) 
8 (9.3) 
8 (9.3) 
3 (3.5) 
1 (1.2) 
14 (16.3) 
10 (11.6) 
10 (11.6) 
6  (7) 
2 (2.3) 
1 (1.2) 
29 (33.7) 
18 (20.9) 
18 (20.9) 
14 (16.3) 
5 (5.8) 
2 (2.3) 
 
Weight (kg), (Mean + SD) 86.4 + 25.7 83.7 + 25.7 84.8 + 25.6 0.553 
BMI, n (%)       
Normal < 25 
Overweight > 25 <30 
Obese > 30  
16 (18.6) 
7 (8.1) 
20 (18.6) 
17 (19.8) 
8 (9.3) 
18 (21) 
33 (38.3) 
15 (17.4) 
38 (44.2) 
0.904 
APACHE II*, (Mean + SD)  23.4 + 5.3 22.6 + 4.7 23 + 5 0.431 
Ventilator days, Mean + SD 5.7 + 4.7 8.3 + 6.4 6.9 + 5.7 0.039 
ICU days, (Mean + SD) 10.6 + 11.6 13.5 + 10.5  12.6 + 11.1 0.227 
Hospital days, (Mean + SD) 15.4 + 13.5 17.5 + 13  16.4 + 13.3 0.467 
Re-intubation < 24 hours, n (%) 4 (4.7) 7 (8.1) 11 (12.8) 0.355 
Mortality, n (%) 17 (19.8) 14 (16.3) 31 (36) 0.501 
Number of admissions last year,  (Mean 
+ SD) 1.1 + 1.3 0.7 + 1.2  0.9 + 1.2  
0.095 
History of Substance abuse, n (%) 6 (7) 7 (8.1) 13 (15.1) 0.764 
Psychiatric History, n (%) 15 (17.4) 2 (2.3) 17 (19.8) 0.001 
Insurance, n (%)       0.924 
Public 
Private 
Other 
32 (37.2) 
7 (8.1)  
4 (4.7) 
33 (33.9) 
7 (8.1) 
3 (3.5) 
65 (75.6) 
14 (16.3) 
7 (8.1) 
 
 *Variables used in propensity score 
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Time-to-Extubation – Primary Outcome  
The time-to-extubation between the FA and CR groups was analyzed using time-to event 
analysis with Cox proportional hazards regression.  Patients were censored by death, self-
extubation and all extubations not according to medical protocol, transfer to another institution, 
re-intubation within 24 hours, and intubation up to 28 days and beyond. Accounting for 
censoring of the time-to-extubation allows the patient to attribute time up to the point of 
censoring. 
Kaplan Meier analysis with the log-rank test was used to determine any univariate 
differences between the two groups in the time-to-extubation.(Figure 5) The graph shows that 
there is not a significant difference between the two groups with the two lines crossing multiple 
times (p= 0.2)      
Using backward elimination in the model selection process, which variables had any 
relevant effect on the time-to-extubation outcome were included in the final model.  The 
backward elimination selection procedure used a probability to stay value of 0.25.   
In the multivariable Cox proportional hazards regression models, the univariate 
unadjusted models demonstrated that Fentanyl alone in a sedation protocol was not worse of in 
terms of the length of time-to-extubation than those who received conventional sedation [HR = 
0.7, 95% CI = (0.47, 1.18)] and this was confirmed in when we accounted to patient socio-
demographic and clinical characteristics in the adjusted model. This was interesting due to the 
differences shown between the two groups with univariate t test (p= 0.039).  Several variables 
were not selected for inclusion into the adjusted model including race, age, re-intubation within 
less than 24 hours, and number of hospital visits in the last year.  The only variable that 
demonstrated a significant difference in both the univariate and adjusted model was the duration 
26 
 
of admission at the ICU [Unadjusted HR = 0.9, 95% CI = (0.83, 0.93); Adjusted HR = 0.9, 95% 
CI = (0.82, 0.92)]. Shorter ICU days were observed to be associated with reduced duration of 
ventilation. This could be explained because the majority of patients who inhabit the ICU are 
ventilated and ICU length of stay is highly correlated to patient’s time on the ventilator. Other 
variables included in the model were the gender, insurance status, and substance abuse history. 
Females showed a significant reduction in the time-to-extubation in the adjusted model [HR 0.5, 
95% CI = (0.32, 0.88)].  Both insurance status and substance abuse history did not show a 
statistically significant effect on duration of patient intubation.  (Figure 6)  
Figure 5. Kaplan Meier Graph 
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Secondary Outcomes 
ICU Length of Stay 
General linear regression modeling technique was used to determine predictors of ICU 
length of stay. The univariate unadjusted model variables that showed any significant effect on 
ICU length of stay included the gender. Females were associated with a surprising reduction in 
ICU length of stay (Parameter estimate -5.6, p < 0.001) compared to males.  Patients who were 
re-intubated within 24 hours of first extubation also had a significantly longer length of stay in 
the unadjusted model (Parameter estimate 9.4, p < 0.001). This may be expected as patients who 
fail extubation are known to have a longer ICU length of stay.  Patients in the FA group did not 
have a statistically significant reduction in ICU length of stay in either the unadjusted (p >0.05) 
or adjusted model (p >0.05) compared to the CR group. In the adjusted model the only variable 
that showed any significant reduction on ICU length of stay was gender. Females were more 
likely than males to have a reduction in the ICU length of stay (parameter estimate -7.1, 95% p 
value < 0.001).  Having public insurance was associated with a significant increase in ICU length 
of stay (parameter estimate 10.4, p < 0.001). The gender difference on length of stay and public 
insurance are discussed further in the discussion section.  All other variables in the adjusted 
model did not show any trend or significant difference in the length of ICU stay. (Table 7) 
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Risk of ICU Mortality 
Binary logistic regression was used to determine variables that would potentially reduce 
or increase the risk of ICU mortality.  In the multivariable logistic regression model, there were 
no trends in mortality with age [OR=1.0, 95% CI = (1.0, 1.1)] and ICU days [OR=1.0, 95% CI = 
(1.0, 1.1)].  The CR group did show a trend towards less mortality [OR=0.7, 95% CI = (0.3, 
1.8)].  Insurance status did not have any statistically significant effect on the risk of mortality 
[OR(Private) = 2.5, 95% CI = (0.3, 22.4); OR (Public) = 2.7, 95% CI = (0.4, 19.4)].  None of the 
other variables showed any significant effect or trend in mortality in both the unadjusted or 
adjusted models (Table 8). 
Table 8. Relative Risk of Mortality 
  Unadjusted Model 
(Univariate Statistics) 
Adjusted Multivariable 
Model 
Effect Ref Odds
Ratio
95% Odds 
Ratio
95% 
Confidence 
Limits 
Confidence Limits 
Age (years) 1.0 1.0 1.1 1.1 1.0 1.1 
ICU length of Stay 1.0 1.0 1.1 1.0 1.0 1.1 
insurance Private vs. 
Other 
Other 2.5 0.3 22.4 0.8 0.1 9.1 
insurance Public vs. 
Other 
Other 2.7 0.4 19.4 0.7 0.1 7.3 
Conventional regimen vs. 
Fentanyl 
Fentanyl 0.7 0.3 1.8 0.6 0.2 1.8 
Race Other vs White White 0.6 0.2 2.3 0.6 0.1 2.8 
Psychiatric History (Y/N) No 1.8 0.6 5.2 1.7 0.4 7.3 
Substance Abuse  (Y/N) No 0.3 0.1 1.5 0.8 0.1 4.8 
BMI Obese vs. Normal Normal 0.3 0.1 0.7 0.2 0.1 0.6 
BMI Overweight vs. 
Normal 
Normal 0.3 0.1 1.2 0.3 0.1 1.3 
Number of hosp visits in 
the last year  
0.9 0.6 1.3 0.8 0.5 1.3 
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Risk of Re-Intubation within 24 hours of Extubation 
This model was used to assess the relative risks of being re-intubated within twenty-fours 
of extubation comparing the FA group to the CR group. This model was used to determine what 
factors predict when extubation fails.  Only eleven patients out of the eighty-six were re-
intubated, which goes along with the demographics table showing no difference between the two 
groups.  There were no significant differences with any of the variables in the unadjusted or 
adjusted model.  Age, ICU length of stay, gender, race, substance abuse, and number of hospital 
visits had 95% CI for the odds ratios than enclosed the null value (Table 8). Patients with a BMI 
in the overweight category had an odds ratio of 3.8 as compared to normal, but again this was not 
statistically significance. Since re-intubation seems a rare event in this group, a larger population 
of patients undergoing MV may be needed to have a meaningful discussion. (Table 9)  
Table 9. Relative Risk of Re-intubation 
Unadjusted Adjusted 
Effect Ref 
Odds 
Ratio 
95% 
Odds 
Ratio 
95% 
Confidence 
Limits 
Confidence 
Limits 
Age (years)   1.1 1.0 1.1 1.1 1.0 1.1 
ICU length of Stay   1.0 1.0 1.1 1.0 1.0 1.1 
insurance Private vs. Other Other 1.7 0.0 56.5 0.8 0.0 29.8 
insurance Public  vs. Other Other 2.8 0.1 65.1 1.0 0.0 29.4 
Gender Female Male 0.5 0.1 1.9 0.5 0.1 2.1 
Conventional regimen vs. Fentanyl CR 1.8 0.5 6.4 0.7 0.2 3.0 
Psychiatric History (Y/N) No 0.5 0.1 3.3 1.2 0.2 8.4 
Race Other vs White White 0.8 0.1 5.3 2.1 0.3 14.6 
BMI Obese  vs. Normal Normal 3.5 0.8 16.0 3.4 0.7 16.0 
BMI Overweight vs. Normal Normal 1.3 0.1 11.5 1.4 0.2 10.8 
Substance Abuse  (Y/N) No 0.7 0.1 4.7 0.7 0.1 6.5 
Number of hospitalizations in the past  
year 
  0.9 0.5 1.6 0.9 0.5 1.6 
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Discussion 
The aim of this study was to compare the FA group to CR in reduction in time to 
extubation and ICU length of stay, in hospital mortality, and proportion of re-intubations within 
24 hours among the two groups.  To acquire balanced retrospective cohort of patients, a 
propensity scoring technique was used based on APACHE II scores, reasons for intubation, and 
admission diagnosis.  This provided an effective method of selecting patients since the 
characteristics of the two groups were well matched at the selection of patients who met initial 
inclusion and exclusion criteria.  
The comparison of FA to CR was to show that the effect of a Fentanyl alone on the 
duration of intubation was not worse off than that of conventional regimen. No difference was 
shown in the Cox proportional hazard regression model.  This is interesting in the fact that this 
was first time this type of analysis had been done (time-to-event) and the results demonstrated 
that groups are comparable. This information coupled with the univariate analysis where FA had 
statistically significant reduction in the mean ventilator days will lead to larger retrospective 
(multicenter) or prospective randomized control trials to elucidate the potential advantage 
between the two groups.   
In the Cox proportional hazard model the critical estimate was ICU length of stay.  This 
should not be a surprising since there is expected a relationship between ventilator days and ICU 
length of stay.  A study by Arabi et al. researching resource utilization of patients with prolonged 
stays in the ICU, demonstrated that ICU length of stay and ventilator days had a high correlation 
(r2 =0.89, p <0.001)43.    
The other variable to have an effect in the model was being gender. Females were more 
likely than males to have a reduced time to extubation. The authors could not find any data 
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correlating gender affecting time to extubation.  It is difficult to determine whether this is just an 
artifact of the data set (was selected from a single center) or selection bias and sample size. It is 
anticipated that, this will be conformed in a larger much more structured study later.  
Secondary Outcomes Discussion 
In the linear regression model the Fentanyl alone group appeared to not affect ICU length 
of stay, after adjusting for other variables and balancing the comparison with propensity scores, 
which should remove any medical difference to the extent possible in this data.  Among ICU 
patients and especially when dealing with sedation and mechanical ventilation, there are several 
variables that can affect outcomes. In a recent trial where sedation vacations were compared to 
light sedation protocol, there was not a difference in the length of ventilator days44.  A study by 
Strom et al. where patients with no sedation (morphine boluses allowed for pain) compared to 
sedation with a daily interruption verified a significant increase in ventilator free days in the no 
sedation group (p <0.05)45. These two trials have a couple of things in common, such as low 
nursing to patient ratios (1:1 in the no sedation study) and extensive education provided to the 
nurses in sedation practices.  The inability to show a difference between the two groups in ICU 
days may be influenced by the quality of care and the education provided to the clinicians at the 
point of care.  On the other hand, as discussed previously, the correlation between ventilator days 
and ICU length of stay leads one to believe that sedation choice will not affect  ICU length of 
stay unless it first reduces ventilator days. Larger multicenter trials are needed to determine the 
effect of sedation on ICU length of stay.  
The final two models looked at mortality and re-intubation within 24 hours of extubation. 
Neither model showed any significant differences in the risks of mortality or re-intubation 
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related to any of the variables. Mortality is affected by several factors that were controlled with 
the propensity matching.   
Strengths 
This trial used propensity scoring which allowed the authors to match cases in an 
observational retrospective sample on multiple variables. This allowed for a well-matched study 
and decreased the retrospective selection bias. This is the first trial that looked at time-to-
extubation.  Previous research on analgosedation has focused on the ability to increase ventilator 
free days or comparing time spent in the optimal level of sedation.  
Limitations  
This was a single center retrospective study in a community teaching hospital medical 
ICU. Even with propensity scoring the risk of selection bias is still present. Some of the 
secondary analysis had limited events occur, which makes it hard to analyze the model.  
Conclusion 
A single-center retrospective cohort study demonstrated that fentanyl alone and 
conventional regimen are non-inferior to each other in the time-to-event analysis.  This study 
was a pilot study and therefore larger more robust study is needed to ascertain the true clinical 
difference between the two groups. 
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